research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
Search
for
Sort by
Research
90-120 / 1000+ resultsresearch Med Check
Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
research Efficacy of oral retinoids in treatment-resistant lichen planopilaris
Oral retinoids may help some patients with hard-to-treat lichen planopilaris, but more research is needed.
research Reporting on Adverse Clinical Events
Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
research Cardiometabolic Risk Factors in Rosuvastatin-Treated Men with Mixed Dyslipidemia and Early-Onset Androgenic Alopecia
Rosuvastatin improves lipid levels, reduces inflammation, but worsens insulin sensitivity in men with early-onset hair loss.
research Hypothyroidism in Thyroid Carcinoma Follow-up: Orlistat May Inhibit the Absorption of Thyroxine
Orlistat might block the body's ability to absorb thyroid medication.
research Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
research Use of Metformin versus Chromium Picolinate in the Management of Polycystic Ovarian Syndrome: A Randomized Controlled Clinical Trial
Chromium picolinate was better tolerated than metformin for PCOS with fewer side effects.
research Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome
Both metformin and pioglitazone improve PCOS symptoms, but pioglitazone is a good alternative for those who can't take metformin.
research Reversible hair loss in a patient with cicatricial alopecia: A case of regrowth associated with pioglitazone use
Pioglitazone use was linked to hair regrowth in a patient with permanent hair loss from cicatricial alopecia.
research Finasteride/spironolactone
research USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
research GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity
GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.
research New drugs: Iobenguane sulfate
Lifestyle changes are more effective than metformin in reducing type 2 diabetes risk in women with PCOS.
research Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
research Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
GLP-1 agonists may increase the risk of hair loss.
research By the way, doctor. Finasteride has been prescribed for my BPH. I think that the most frequent side effect is erectile dysfunction or loss of sexual desire. Would Levita or a similar drug (like Viagra or Cialis) overcome the side effects of finasteride?
research Treatment of insulin resistance with tirzepatide leading to improvement of hair loss
Tirzepatide may improve hair loss by reducing insulin resistance.
research Recalcitrant lichen planopilaris treated with upadacitinib: a case series
Upadacitinib may effectively treat resistant lichen planopilaris.
research Type 2 Diabetes, Metabolic Syndrome and Lipid Metabolism
Type 2 diabetes in youth is increasing, with high treatment failure rates and more severe than Type 1; certain drugs can lower lipid levels effectively with varying side effects, and apples may benefit heart health like statins but with fewer side effects.
research Reduction of oral tetracycline of lipolysis of triglycerides in hair lipid
Oral tetracycline reduces fat breakdown in hair lipids.
research Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
research Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris.
Low-dose naltrexone helps reduce symptoms and slow down lichen planopilaris without side effects.
research Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the BSCL2 Gene: Results From the First-year
Metreleptin treatment significantly improved metabolic health in a boy with congenital generalized lipodystrophy.
research Ann Robinson’s research reviews —12 May 2022
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
research Impact of lisinopril on cardiometabolic risk factors in men with hypertension and early-onset androgenetic alopecia
Lisinopril improves heart health more in men with normal hair than those with early hair loss.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.